Business & Economics
Novo Nordisk’s CagriSema Misses Non-Inferiority in Head-to-Head Phase 3, $475 B Valuation Gain Evaporates
On 23 Feb 2026 Novo Nordisk revealed that CagriSema cut weight by 23% after 84 weeks but still under-performed Eli Lilly’s tirzepatide, triggering a double-digit share plunge and wiping out the market-cap windfall Wegovy once created.
Focusing Facts
- REDEFINE-4 enrolled 809 adults with obesity; CagriSema 2.4/2.4 mg produced 23.0% mean weight loss versus 25.5% for tirzepatide 15 mg, failing the non-inferiority primary endpoint.
- Novo Nordisk stock fell more than 16% on 23 Feb 2026, erasing roughly US$475 b in market value and sending the share price back to June 2021 levels.
- Despite the setback, Novo filed CagriSema with the FDA in Dec 2025 and plans a higher-dose Phase 3 trial starting H2 2026, with an FDA decision expected late 2026.
Context
Drug-on-drug showdowns have redrawn pharma pecking orders before: Pfizer’s Lipitor (1997) supplanted Merck’s Zocor by delivering a few extra percentage points of LDL reduction, a margin similar to tirzepatide’s current edge. The CagriSema miss underscores two century-long trends: (1) chronic-disease markets gravitate toward the therapy that shows the absolute best hard-endpoint number, even if safety is comparable; (2) capitalisation in modern pharma is increasingly binary, hinging on single franchise read-outs rather than diversified pipelines. Over a 100-year horizon the episode is unlikely to decide whether pharmacological weight control becomes standard—combination incretin-amylin agents, or entirely new pathways such as GLP-1/glucagon duals or gene editing, will keep advancing. Yet it does mark a turning point in shifting market power from Europe’s Novo to U.S.-based Lilly, potentially redefining where next-generation metabolic research clusters and how health-system cost curves bend if the most potent agent wins broad reimbursement.
Perspectives
Mainstream financial-investor media
Reuters, The Motley Fool, Yahoo Finance, Morningstar, etc. — They cast CagriSema’s Phase 3 under-performance versus Lilly’s tirzepatide as a serious competitive blow that wiped billions from Novo Nordisk’s value and clouds its long-term obesity franchise. Because these outlets serve traders and market-watchers, they amplify short-term share-price drama and may underplay scientific nuances that do not move the stock ticker.
Novo Nordisk corporate communications and sympathetic coverage
company release carried by Taiwan News, executive interview on Bloomberg — They emphasize the still-robust 23 % weight loss, safety profile and forthcoming higher-dose trials, arguing CagriSema remains a pioneering combo therapy with significant potential. As a self-authored or company-guided narrative, it spotlights positives and downplays the failure to meet the non-inferiority endpoint to reassure regulators, investors and patients.
Plaintiffs’ securities-litigation firms press releases
wallstreet:online, Barchart.com — online, Barchart.com) They frame the trial miss as grounds for shareholder lawsuits, suggesting Novo Nordisk may have misled investors and caused sizable losses. Litigation outfits profit from class actions, so they highlight potential wrongdoing and monetary damages early, even before any legal findings are established.
Like what you're reading?